The first Health Technology Assessment for the Acute Treatment of Migraine Attacks and Prevention has been published in Cephalalgia by the Clinical Trials Subcommittee of the International Headache Society.
The investigators explored the relationships between headache frequency and characteristics, medication use, and quality of life in patients with chronic migraine and medication overuse headache.
Researchers assessed safety reports on erenumab, galcanezumab, and fremanezumab, and conducted disproportionality analyses regarding suspected adverse drug reactions during pregnancy and lactation.
The objective of this post hoc analysis is to better assess the benefits of fremanezumab in patients who responded to treatment during 2 phase 3 HALO clinical trials.
